Answers are grounded in this paper and cite their sources.
Plaque psoriasis can occur anywhere on the body, including the scalp. Roflumilast foam 0.3% is an advanced targeted topical treatment that is a phosphodiesterase 4 inhibitor formulated without known skin-irritating excipients, including fragrances, ethanol, or propylene glycol. Efficacy and safety of roflumilast foam 0.3% were demonstrated in patients with plaque psoriasis in the 8-week, double-blind, randomized, parallel group, vehicle-controlled, phase 3 ARRECTOR (NCT05028582) trial. Patterns of improvement in psoriasis over time on the scalp and body of patients in the ARRECTOR trial were assessed. Patients aged ≥12 years with at least moderate psoriasis of the scalp and mild psoriasis of the body were randomized 2:1 to apply roflumilast foam 0.3% or vehicle foam once daily for 8 weeks. Co-primary endpoints were Investigator Global Assessment of the scalp (S-IGA) and of the body (B-IGA) success, defined as achievement of clear (0) or almost clear (1) plus ≥2‑grade improvement from baseline. Key secondary endpoints were Scalp Itch-Numeric Rating Scale (SI-NRS) and Worst Itch-NRS (WI-NRS) success, defined as ≥4-point improvement from baseline for patients with baseline score ≥4. Safety and tolerability were also assessed. Among 432 patients, most had moderate S-IGA (85.6%) and B-IGA (67.1%) at baseline. Across time points, higher proportions of patients treated with roflumilast foam versus vehicle achieved S-IGA success (week 2: 30.4% vs 11.7%; week 4: 53.8% vs 19.5%; week 8: 66.4% vs 27.8%; each P<0.0001) and B-IGA success (12.7% vs 8.0%, P=0.25; 32.8% vs 12.1%, P<0.0001; 45.5% vs 20.1%; P<0.0001). Itch symptoms improved (least-squares mean improvement) with roflumilast versus vehicle within 24 hours of the first application on the scalp (SI-NRS: 0.44 vs 0.09; P<0.02) and body (WI-NRS: 0.42 vs 0.01; P<0.01) and throughout the study. Significantly higher proportions of patients in the roflumilast versus the vehicle group achieved SI-NRS success at week 2 (25.2% vs 8.0%; P<0.001) and through week 8 (65.3% vs 30.3%; P<0.0001), as well as WI-NRS success (week 2: 23.3% vs 10.9%, P<0.05; week 8: 63.1% vs 30.1%, P<0.0001). Related adverse events were reported for 16 (5.7%) and 3 (2.0%) patients in the roflumilast and vehicle groups, respectively. Overall, discontinuation of study treatment because of a treatment-emergent adverse event was 2.1%. Across assessment time points, no evidence of irritation at the application site was reported by investigators for ≥99.6% of patients in the roflumilast group. A severe hot tingling/stinging sensation was reported by 1 (0.4%) patient after the first application of roflumilast and at the week 2 assessment, and by no patients at subsequent assessments. Roflumilast foam 0.3% was well tolerated and significantly improved psoriasis severity on the scalp and body within 8 weeks, and itch intensity was significantly improved within 24 hours of the first application and throughout the study. These data support roflumilast foam 0.3% as a therapeutic option in lieu of traditional topical treatments (eg, corticosteroids and vitamin D analogues) for psoriasis, including psoriasis of the scalp.
No takes yet. Share an insight, caveat, or question.
Jaworski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: